Research / COST / Fundamental state Inspectable configuration
State dimensions Filing 0000909832-26-000093 General Corporate
Debt relative to revenue 0th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.debt_to_revenue
2.03% · OPTIONAL · VALID
Capex intensity 95th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
2.12% · OPTIONAL · VALID
Operating cash generation 70th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
5.22% · OPTIONAL · VALID
Revenue growth 70th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
10.14% · CORE · VALID
Inventory pressure 0th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
6.37% · OPTIONAL · VALID
Gross margin 75th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
12.82% · CORE · VALID
Operating margin 90th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
3.85% · CORE · VALID
SBC intensity 50th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
0.30% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 17 states Self-history eligible
Aug 28, 2016 0/6 normalized Level 3 Nov 20, 2016 0/6 normalized Level 3 Feb 12, 2017 0/6 normalized Level 3 May 7, 2017 0/6 normalized Level 3 Sep 3, 2017 0/7 normalized Level 3 Nov 26, 2017 0/7 normalized Level 3 Feb 18, 2018 0/7 normalized Level 3 May 13, 2018 0/7 normalized Level 3 Sep 2, 2018 6/7 normalized Level 3 Nov 25, 2018 6/7 normalized Level 3 Feb 17, 2019 6/7 normalized Level 3 May 12, 2019 6/7 normalized Level 3 Sep 1, 2019 6/7 normalized Level 3 Nov 24, 2019 7/8 normalized Level 3 Feb 16, 2020 7/8 normalized Level 3 May 10, 2020 7/8 normalized Level 3 Aug 30, 2026 8/8 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 8.04%
Current 2.03%
Delta -6.01% Capex Intensity Increased
Previous 2.00%
Current 2.12%
Delta 0.12% Cash Generation Increased
Previous 4.89%
Current 5.22%
Delta 0.33% Growth Decreased
Previous 11.58%
Current 10.14%
Delta -1.44% Inventory Pressure Decreased
Previous 27.53%
Current 6.37%
Delta -21.16% Margin Increased
Previous 12.77%
Current 12.82%
Delta 0.05% Profitability Decreased
Previous 3.99%
Current 3.85%
Delta -0.14% Sbc Intensity Increased
Previous 0.17%
Current 0.30%
Delta 0.14% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Aug 31, 2025
Similarity 89%
Compared 8 dimensions
Coverage 100% Growth 20.0 · Margin 5.0 · Profitability 5.0 · Sbc Intensity 0.0 · Capex Intensity 15.0 · Cash Generation 15.0 · Inventory Pressure 0.0 · Balance Sheet Leverage 0.0 Feb 15, 2026
Similarity 78%
Compared 8 dimensions
Coverage 100% Growth 5.0 · Margin 5.0 · Profitability 5.0 · Sbc Intensity 15.0 · Capex Intensity 25.0 · Cash Generation 40.0 · Inventory Pressure 25.0 · Balance Sheet Leverage 25.0 May 12, 2024
Similarity 71%
Compared 8 dimensions
Coverage 100% Growth 20.0 · Margin 25.0 · Profitability 10.0 · Sbc Intensity 40.0 · Capex Intensity 40.0 · Cash Generation 6.8 · Inventory Pressure 40.0 · Balance Sheet Leverage 25.0 Sep 2, 2018
Similarity 71%
Compared 6 dimensions
Coverage 75% Margin 50.0 · Profitability 27.5 · Sbc Intensity 0.0 · Capex Intensity 32.5 · Inventory Pressure 25.0 · Balance Sheet Leverage 12.5 Feb 16, 2025
Similarity 70%
Compared 8 dimensions
Coverage 100% Growth 20.0 · Margin 35.0 · Profitability 5.0 · Sbc Intensity 20.0 · Capex Intensity 45.0 · Cash Generation 35.0 · Inventory Pressure 35.0 · Balance Sheet Leverage 25.0 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.